Amyris Repays in Cash April 2019 Convertible Note Debt
April 16, 2019 16:27 ET
|
Amyris, Inc.
EMERYVILLE, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris Provides Update on Resolution of April 2019 Convertible Note Maturity
April 15, 2019 08:30 ET
|
Amyris, Inc.
EMERYVILLE, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-K
April 09, 2019 17:00 ET
|
Amyris, Inc.
EMERYVILLE, Calif., April 09, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris Delivers on First CBD Milestone; Earns $10 Million
March 29, 2019 08:33 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris to Present April 15 at Paradigm Capital Biosynthesis Conference – Exploring the Most Disruptive Technology in the Cannabis Industry
March 27, 2019 08:34 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris to Present at H.C. Wainwright Global Life Sciences Conference on April 8, 2019
March 25, 2019 08:30 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Announces Signing of $300 Million Definitive Cannabinoid Agreement
March 18, 2019 16:28 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Q4 2018 GAAP revenue of $19.4 million, compared with GAAP revenue of $80.6 million (reflected $57.3 million during period for agreement with...
Amyris Finalizes Cannabinoid Development, Licensing and Commercialization Agreement Containing $300 Million of R&D and Milestone Payments and a Long-Term Royalty Stream
March 18, 2019 16:19 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris to Present at 31st Annual Roth Conference on Tuesday, March 19, 2019
March 12, 2019 08:30 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty...
Amyris to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Monday, March 18, 2019
March 05, 2019 08:30 ET
|
Amyris, Inc.
EMERYVILLE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the fourth quarter and fiscal year ended December 31, 2018 after market close on...